| Enhancer ID: | E_01_0594 |
| Species: | human |
| Position : | chr1:8002032-8004032 |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Triple-negative breast cancer |
| Pubmed ID: | 32432675 |
| Enhancer experiment: | qPCR?ChIP-seq |
| Enhancer experiment description: | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
| Target gene : | ERRFI1 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
| TF name : | -- |
| TF experiment: | qPCR?ChIP-seq |
| TF experiment description: | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
| Enhancer function : | Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
Taken together, our findings suggest that the progressive loss of the GC-dependent regulation and anti-tumorigenic function of ERRFI1 influences BCa progression and may contribute to the unfavorable effects of GC therapy in TNBC. |
| SNP ID: | -- |
| GeneName | Pathway Name | Source | Gene Number |
|---|